Another study suggested that combined QE and simvastatin attenuated hepatic fibrosis in rats by lowering serum levels of GOT, GPT, ALP, decreasing hepatic mRNA levels of sphingosine kinases type 1 (SphK1) and NLRP3 and elevating total antioxidant capacity, glutathione and Nrf2 expression levels, suggesting that targeting the SphK1/NLRP3 pathway could be a prospective therapeutic strategy against liver fibrosis (Salama et al., 2024). The gene discussed is SPHK1; the disease is Hepatic fibrosis.